TMLI, Cyclophosphamide, and Etoposide as Conditioning for Allo-HSCT in High-Risk ALL or AML

Phase 2, open-label, single-arm trial of etoposide and cyclophosphamide in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Incidence of toxicity, scored on both the Bearman Scale and National Cancer Institute Common Terminology Criteria version 4.03 and Progression-Free Survival up to 2 years. Started May 2014; status: active, not recruiting.